Results 131 to 140 of about 8,864 (209)

MRI and ¹⁸F-fluorothymidine PET-MR for the early evaluation of renal and bone marrow effects in ¹⁷⁷Lu-DOTATATE therapy. [PDF]

Endocr Oncol
Dimopoulou Creusen A, Johansson E, Hagmar P, Ahlström H, Granberg D.   +4 more
europepmc   +1 more source

Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumors. [PDF]

J Nucl Med
Tamborino G, Engbers P, de Wolf TH, Reuvers TGA, Verhagen R, Konijnenberg M, Nonnekens J.   +6 more
europepmc   +1 more source

Phase II Study of ¹⁷⁷Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. [PDF]

J Clin Oncol
Lin FI, Del Rivero J, Carrasquillo JA, Jha A, Zou J, Shamis I, Talvacchio S, Turkbey B, Huang EP, Shih J, Klubo-Gwiezdzinska J, Mena E, Lindenberg L, Teng Y, Escorcia FE, Chen C, Herscovitch P, Millo C, Choyke PL, Pacak K.   +19 more
europepmc   +1 more source

Expanding the therapeutic horizon of 177Lu-DOTATATE: a review of current evidence

Expanding the therapeutic horizon of 177Lu-DOTATATE: a review of current evidence
Neuroendocrine tumors (NETs) are a heterogenous group of neoplasms originating from neuroendocrine cells, most frequently found in the gastrointestinal tract and pancreas. A defining feature of NETs is the overexpression of somatostatin receptors (SSTRs), particularly subtype 2 (SSTR2), which is the primary target for both diagnostic imaging and ...
openaire   +1 more source

Very good effect of rescue treatment with ¹⁷⁷Lu-DOTATATE in the patient with advanced metastatic atypical lung carcinoid. [PDF]

Rep Pract Oncol Radiother
Poniatowska ME, Galińska B, Kurkowska S, Malarz M, Piwowarska-Bilska H, Becht R, Birkenfeld B.   +6 more
europepmc   +1 more source

Molecular Deconvolution of Circulating "Other Cells": A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients Receiving ¹⁷⁷Lu-DOTATATE PRRT. [PDF]

Cancer Med
Padwal MK, Parghane RV, Basu S, Basu B.
europepmc   +1 more source

Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in ¹⁷⁷Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial. [PDF]

JMIR Res Protoc
Yagihashi T, Miwa K, Miyaji N, Sugimoto S, Hayakawa H, Kobayashi N, Takano S, Murai T.   +7 more
europepmc   +1 more source

Success of ¹⁷⁷Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor. [PDF]

Endocr Oncol
Wolf KI, Lu Z, Hesseltine EA, Wong KK, Worden FP, Else T.   +5 more
europepmc   +1 more source

Delayed and Long-Lasting Response to 177Lu-DOTATATE in a Head and Neck Paraganglioma: Case Report and Literature Review. [PDF]

Case Rep Oncol
Ruffini Egea S, Campos Ramírez SE, Pascual de la Fuente NP, Monreal Cepero ML, Mocha Campillo F, Trincado Cobos P, Antón Torres A, Martínez Trufero J.   +7 more
europepmc   +1 more source

Evaluation of using small volume of interest regions for clinical kidney dosimetry in ¹⁷⁷Lu-DOTATATE treatments. [PDF]

EJNMMI Phys
Khan J, Rydèn T, Van Essen M, Svensson J, Bernhardt P.   +4 more
europepmc   +1 more source